Anti-Hyperalgesic Efficacy of Acetyl L-Carnitine (ALCAR) Against Visceral Pain Induced by Colitis: Involvement of Glia in the Enteric and Central Nervous System.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Oct 2023
Historique:
received: 13 06 2023
revised: 22 09 2023
accepted: 25 09 2023
medline: 23 10 2023
pubmed: 14 10 2023
entrez: 14 10 2023
Statut: epublish

Résumé

The management of abdominal pain in patients affected by inflammatory bowel diseases (IBDs) still represents a problem because of the lack of effective treatments. Acetyl L-carnitine (ALCAR) has proved useful in the treatment of different types of chronic pain with excellent tolerability. The present work aimed at evaluating the anti-hyperalgesic efficacy of ALCAR in a model of persistent visceral pain associated with colitis induced by 2,4-dinitrobenzene sulfonic acid (DNBS) injection. Two different protocols were applied. In the preventive protocol, ALCAR was administered daily starting 14 days to 24 h before the delivery of DNBS. In the interventive protocol, ALCAR was daily administered starting the same day of DNBS injection, and the treatment was continued for 14 days. In both cases, ALCAR significantly reduced the establishment of visceral hyperalgesia in DNBS-treated animals, though the interventive protocol showed a greater efficacy than the preventive one. The interventive protocol partially reduced colon damage in rats, counteracting enteric glia and spinal astrocyte activation resulting from colitis, as analyzed by immunofluorescence. On the other hand, the preventive protocol effectively protected enteric neurons from the inflammatory insult. These findings suggest the putative usefulness of ALCAR as a food supplement for patients suffering from IBDs.

Identifiants

pubmed: 37834289
pii: ijms241914841
doi: 10.3390/ijms241914841
pmc: PMC10573187
pii:
doi:

Substances chimiques

Acetylcarnitine 6DH1W9VH8Q
2,4-dinitrofluorobenzene sulfonic acid 143134-35-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : University of Florence
ID : N/A
Organisme : Ministry of Education, Universities and Research
ID : N/A
Organisme : Alfasigma S.p.A
ID : N/A

Références

Biomedicines. 2021 Nov 12;9(11):
pubmed: 34829900
Pediatr Res. 2006 Jul;60(1):93-6
pubmed: 16690958
World J Gastroenterol. 2021 Mar 7;27(9):794-814
pubmed: 33727771
Ann Transl Med. 2015 Jun;3(10):136
pubmed: 26207229
Neurochem Int. 2012 Sep;61(4):444-54
pubmed: 22709675
J Neurosci Res. 2009 Jan;87(1):200-7
pubmed: 18709658
Neurosci Lett. 1989 Dec 15;107(1-3):251-5
pubmed: 2616037
Curr Res Food Sci. 2021 May 28;4:336-344
pubmed: 34124692
Neuropharmacology. 2004 Aug;47(2):286-94
pubmed: 15223307
J Clin Med. 2021 Jul 31;10(15):
pubmed: 34362210
Foods. 2022 Feb 17;11(4):
pubmed: 35206057
Gut. 2017 May;66(5):966-974
pubmed: 28232472
Nutrients. 2022 Jul 29;14(15):
pubmed: 35956313
Trends Neurosci. 2022 Feb;45(2):158-170
pubmed: 34906391
J Pain Res. 2018 Sep 21;11:1971-1982
pubmed: 30288092
J Neurochem. 2010 Aug;114(3):820-31
pubmed: 20477950
Neurochem Res. 2016 Feb;41(1-2):86-95
pubmed: 26433381
Neurosci Lett. 2000 May 5;285(1):71-5
pubmed: 10788710
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):571-587
pubmed: 33731961
Life Sci. 2006 Jan 18;78(8):803-11
pubmed: 16253281
Naunyn Schmiedebergs Arch Pharmacol. 1997 Apr;355(4):545-9
pubmed: 9109373
Gut Microbes. 2022 Jan-Dec;14(1):2027852
pubmed: 35090382
J Physiol. 2016 Oct 15;594(20):5771-5780
pubmed: 26959627
Neuropharmacology. 2014 Apr;79:37-48
pubmed: 24225197
Cell Mol Life Sci. 2021 May;78(10):4713-4733
pubmed: 33770200
Clin Dev Immunol. 2013;2013:948976
pubmed: 23840244
Pain. 2021 May 1;162(5):1305-1321
pubmed: 33259456
Cells. 2020 Jun 21;9(6):
pubmed: 32575844
Front Cell Neurosci. 2013 Jan 30;7:6
pubmed: 23386811
Mol Pain. 2006 Jun 09;2:20
pubmed: 16764720
Cells. 2020 Jul 24;9(8):
pubmed: 32722246
Mol Neurobiol. 2016 Sep;53(7):4286-301
pubmed: 26223802
Trends Pharmacol Sci. 2010 Apr;31(4):153-60
pubmed: 20064669
Gastroenterol Hepatol (N Y). 2018 Apr;14(4):250-252
pubmed: 29942225
CNS Drugs. 2007;21 Suppl 1:31-8; discussion 45-6
pubmed: 17696591
Neuroscience. 2014 Jun 6;269:143-51
pubmed: 24680856
Front Cell Neurosci. 2017 Aug 08;11:235
pubmed: 28848398
Dig Dis Sci. 2006 Mar;51(3):488-94
pubmed: 16614957
Cell Rep. 2018 May 29;23(9):2678-2689
pubmed: 29847798
J Neurosci Res. 2005 Feb 15;79(4):509-21
pubmed: 15641110
Dig Dis Sci. 2023 Jun;68(6):2414-2426
pubmed: 36808325
J Cell Mol Med. 2015 Feb;19(2):485-500
pubmed: 25521239
Neural Regen Res. 2018 Apr;13(4):692-698
pubmed: 29722322
Gastroenterol Res Pract. 2018 Apr 04;2018:9252984
pubmed: 29849603
Neuroscience. 2010 Feb 17;165(4):1345-52
pubmed: 19925851
Pharmacol Res. 2021 Nov;173:105874
pubmed: 34500063
Neurogastroenterol Motil. 2021 Nov;33(11):e14130
pubmed: 33797165
Front Neurosci. 2020 Nov 05;14:536682
pubmed: 33224019
Transl Psychiatry. 2016 Sep 13;6(9):e888
pubmed: 27622932
Mol Pain. 2022 Jan-Dec;18:17448069221087033
pubmed: 35255745
Neurochem Res. 2017 Jun;42(6):1661-1675
pubmed: 28508995
Neurochem Int. 2012 Jul;61(1):100-7
pubmed: 22549035
Cell Mol Gastroenterol Hepatol. 2019;7(2):433-445
pubmed: 30739868
Biochim Biophys Acta. 2016 Oct;1863(10):2422-35
pubmed: 26828774
Pain. 1998 Mar;75(1):141-155
pubmed: 9539683
Life Sci. 2014 Jun 13;106(1-2):32-9
pubmed: 24786526
Pain. 2021 Oct 1;162(10):2466-2471
pubmed: 34534174
Cell Mol Neurobiol. 2009 Jul;29(5):609-19
pubmed: 19319675
Neuropharmacology. 2012 Oct;63(5):798-805
pubmed: 22722030
Neuropharmacology. 2002 Dec;43(7):1180-7
pubmed: 12504925
Front Neural Circuits. 2021 Aug 17;15:711564
pubmed: 34483848
Neurochem Res. 1990 Jun;15(6):597-601
pubmed: 2215852
Curr Opin Pharmacol. 2012 Feb;12(1):28-34
pubmed: 22040745
Neuroscience. 2010 Jun 2;167(4):1168-74
pubmed: 20302919
Pain. 2013 Dec;154 Suppl 1:S10-S28
pubmed: 23792284
Gastroenterology. 2004 Jun;126(7):1872-83
pubmed: 15188182
Eur J Neurosci. 2007 Aug;26(4):820-7
pubmed: 17714181
ACS Chem Neurosci. 2018 May 16;9(5):901-905
pubmed: 29370524
Clin Transl Gastroenterol. 2014 Mar 20;5:e55
pubmed: 24646507
Curr Pharm Des. 2020;26(12):1277-1285
pubmed: 32048954
Neurogastroenterol Motil. 2016 Apr;28(4):455-62
pubmed: 27010234
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986
Cell Rep. 2020 Sep 8;32(10):108100
pubmed: 32905782

Auteurs

Elena Lucarini (E)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.

Laura Micheli (L)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.

Alessandra Toti (A)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.

Clara Ciampi (C)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.

Francesco Margiotta (F)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.

Lorenzo Di Cesare Mannelli (L)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.

Carla Ghelardini (C)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH